Shashi Tripathi - ImpediMed CTO COO
| IPDQF Stock | USD 0.05 0.00 0.00% |
Insider
Shashi Tripathi is CTO COO of ImpediMed Limited
| Phone | 61 7 3860 3700 |
| Web | https://www.impedimed.com |
ImpediMed Management Efficiency
The company has return on total asset (ROA) of (0.2848) % which means that it has lost $0.2848 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5192) %, meaning that it generated substantial loss on money invested by shareholders. ImpediMed's management efficiency ratios could be used to measure how well ImpediMed manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Michael Hutchinson | LivaNova PLC | 53 | |
| John Davis | Artivion | 59 | |
| James Bullock | Artivion | 64 | |
| Mark Quick | Orthofix Medical | N/A | |
| Jason Edie | Paragon 28 | N/A | |
| Sam Park | Sight Sciences | 63 | |
| Bart Bracy | Anika Therapeutics | N/A | |
| John Ordway | Sight Sciences | N/A | |
| Anne Nunes | Anika Therapeutics | 54 | |
| Erik Mickelson | Paragon 28 | 42 | |
| Brendan Shook | Paragon 28 | N/A | |
| Charles III | Anika Therapeutics | N/A | |
| Lindsey Little | LivaNova PLC | N/A | |
| Michelle Scharfenberg | Avanos Medical | N/A | |
| Mojirade James | Avanos Medical | 57 | |
| David Colleran | Anika Therapeutics | 52 | |
| Michelle Missal | Paragon 28 | N/A | |
| Barbara Schwarzentraub | CONMED | 53 | |
| Andrew Green | Artivion | 52 | |
| Matthew Getz | Artivion | 55 | |
| Daniel Bevevino | Artivion | 61 | |
Management Performance
| Return On Equity | -0.52 | |||
| Return On Asset | -0.28 |
ImpediMed Limited Leadership Team
Elected by the shareholders, the ImpediMed's board of directors comprises two types of representatives: ImpediMed inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ImpediMed. The board's role is to monitor ImpediMed's management team and ensure that shareholders' interests are well served. ImpediMed's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ImpediMed's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David BS, Ex Director | ||
| Nancy Deisinger, VP HR | ||
| Timothy Cruickshank, Chief Officer | ||
| Michael Bassett, Sr Officer | ||
| Shashi Tripathi, CTO COO | ||
| Walton Taylor, Medical Director | ||
| Richard Valencia, MD CEO | ||
| AAICD ACIS, Company Sec | ||
| Dennis Schlaht, VP Technology | ||
| Thomas Schenk, Chief Officer | ||
| Catherine Kingsford, VP Affairs |
ImpediMed Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is ImpediMed a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.52 | |||
| Return On Asset | -0.28 | |||
| Profit Margin | (1.88) % | |||
| Operating Margin | (2.00) % | |||
| Current Valuation | 81.27 M | |||
| Shares Outstanding | 1.79 B | |||
| Shares Owned By Insiders | 13.73 % | |||
| Shares Owned By Institutions | 14.96 % | |||
| Price To Earning | (8.46) X | |||
| Price To Book | 2.74 X |
Currently Active Assets on Macroaxis
Other Information on Investing in ImpediMed Pink Sheet
ImpediMed financial ratios help investors to determine whether ImpediMed Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImpediMed with respect to the benefits of owning ImpediMed security.